Business Context and Reporting Period
Company: Bristol-Myers Squibb Company (BMS)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2007
Business Overview: BMS is a global pharmaceutical and healthcare products company organized into three reportable segments: Pharmaceuticals, Nutritionals, and Other Health Care. The company is currently executing a strategic transition to streamline operations and maximize pipeline value.
Key Financial Metrics
| Metric (in millions) | Three Months Ended June 30, 2007 |
Three Months Ended June 30, 2006 |
Six Months Ended June 30, 2007 |
Six Months Ended June 30, 2006 |
|---|---|---|---|---|
| Net Sales | $4,928 | $4,871 | $9,404 | $9,547 |
| Net Earnings | $706 | $667 | $1,396 | $1,381 |
| Earnings Per Share (Diluted) | $0.36 | $0.34 | $0.71 | $0.70 |
| Operating Cash Flow | N/A | N/A | $1,826 | $928 |
| Working Capital | $4,855 | N/A | N/A | N/A |
| Long-Term Debt | $6,978 | N/A | N/A | N/A |
| Cash & Cash Equivalents | $2,379 | N/A | N/A | N/A |
Note: Operating cash flow and balance sheet items are presented for the six-month period or as of June 30, 2007, where applicable.
Material Changes vs. Prior Period
- Revenue: Net sales increased 1% in Q2 2007 compared to Q2 2006, driven by a 2% favorable foreign exchange impact. For the six months ended June 30, 2007, net sales decreased 1% due to the loss of exclusivity for PRAVACHOL and the impact of generic clopidogrel bisulfate, partially offset by growth in key products like ABILIFY and the SUSTIVA Franchise.
- Profitability: Net earnings increased 6% in Q2 2007 and 1% for the six-month period. The effective tax rate decreased significantly to 16.5% for the six months ended June 30, 2007 (from 25.4% in 2006), largely due to a $105 million tax benefit from the resolution of IRS matters and the re-enactment of the R&D tax credit.
- Product Performance:
- PLAVIX*: Sales remained relatively constant in Q2 ($1.189 billion) but faced an estimated adverse impact of $50–$100 million from generic competition. For the six months, sales were flat ($2.127 billion) with an estimated adverse impact of $250–$350 million.
- PRAVACHOL: Sales declined 59% in Q2 and 69% for the six months due to generic competition following patent expiration.
- ABILIFY*: Sales grew 27% in Q2 and 28% for the six months, driven by strong demand in the U.S. and international markets.
- Restructuring: The company recorded $7 million in restructuring charges in Q2 2007 and $44 million for the six months, related to workforce reductions and streamlining operations.
Guidance, Outlook, and Risks
- PLAVIX* Litigation: A U.S. District Court upheld the validity of the PLAVIX* patent in June 2007, enjoining Apotex from selling generic clopidogrel until 2011. However, Apotex has appealed. The company warns that if Apotex prevails on appeal, renewed generic competition would be material to sales and cash flows.
- Legal Proceedings: The company pleaded guilty to two counts of violating 18 U.S.C. Sec. 1001 regarding false statements to the FTC concerning the PLAVIX* settlement and paid a $1 million fine. Investigations by the FTC and New York State Attorney General remain ongoing. Additionally, a $499 million settlement is in principle for pricing and sales practices investigations.
- Deferred Prosecution Agreement (DPA): The DPA with the U.S. Attorney's Office for the District of New Jersey expired on June 15, 2007, and the criminal complaint was dismissed. The company has no ongoing obligations under the DPA.
- Outlook: Management expects cash generated from operations, existing cash, and marketable securities to be sufficient to cover working capital, capital expenditures, milestone payments, and dividends, provided there is no renewed generic competition for PLAVIX*.
Key Facts for Investor Verification
- Patent Status: Verify the status of the Apotex appeal regarding the PLAVIX* patent, as a loss could trigger immediate generic competition and significant revenue decline.
- Legal Reserves: Confirm the finalization of the $499 million settlement regarding pricing and sales practices and the potential for additional state participation or new claims.
- Product Pipeline: Monitor the FDA and EMEA review timelines for SPRYCEL (target action mid-November 2007) and ixabepilone (target action late October 2007).
- Inventory Levels: Review the "months on hand" data for key products, particularly PARAPLATIN, which showed elevated inventory levels (17.5 months) due to generic competition.
- Tax Position: Assess the sustainability of the 16.5% effective tax rate, which was heavily influenced by a one-time $105 million tax benefit from IRS resolution.